Dainippon Sumitomo Pharma
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, 541-0045, Japan
Overview
"Green Prism", the symbol of Dainippon Sumitomo Pharma Co., Ltd. is a motif in the design of the "Sun"-expressing a lively sense of energy, moving on toward tomorrow; "Light"-to convey the potential and hope of the future; and "Flower"-engendering the joyous and liberated sensation of basking in good health. A design crafted to embody preeminent research and development powers, a thorough support system, the spirit of challenge, and the other stances of Dainippon Sumitomo Pharma-a company bent on supplying all people with the strength to push on toward an even brighter tomorrow. Emanating from the symbol, furthermore, is the image of a network, steadily spreading out into the world.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Health Diagnostics
- Pharmaceutical
Investment portfolio
- Healios
Led · Equity · Mar 2013
Healios (operating as Retina Institute Japan) is a biotechnology company focused on commercializing induced pluripotent stem (iPS) cell technology to treat refractory retinal diseases. Leveraging patents licensed from the renowned research institute RIKEN, the company is developing the world’s first pharmaceutical iPS-cell–derived retinal pigment epithelial (RPE) cells, addressing an estimated $21 billion global market for age-related macular degeneration (AMD). Beyond RPE cells, Healios’ pipeline includes photoreceptor transplantation, broader retinal regenerative medicines, and novel diagnostic methods designed to convert currently untreatable retinal conditions into treatable ones. The company positions itself at the forefront of regenerative medicine and aims to rapidly translate Nobel Prize-winning iPS discoveries into clinical products. A recent strategic investment by Dainippon Sumitomo Pharma (DSP) provides both capital and an exclusive collaboration framework to accelerate development and commercialization. The 1.5 billion JPY equity infusion strengthens Healios’ financial base as it advances toward clinical and commercial milestones.
Team
No current team members are available.